Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T10:44:35.867Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Zidovudine Postexposure Prophylaxis on the Development of HIV-Specific Cytotoxic T-Lymphocyte Responses in HIV-Exposed Healthcare Workers

Published online by Cambridge University Press:  02 January 2015

Ronnie D'Amico ,
Ligia A. Pinto ,
Peter Meyer ,
Alan L. Landay ,
Alan A. Harris ,
Mario Clerici ,
Jay A. Berzofsky ,
Gene M. Shearer  and
Harold A. Kessler
Ronnie D'Amico
Affiliation:
Department of Medicine, Rush Medical College, Chicago, Illinos
Ligia A. Pinto
Affiliation:
National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Peter Meyer
Affiliation:
Department of Preventive Medicine, Rush Medical College, Chicago, Illinos
Alan L. Landay
Affiliation:
Department of Medicine, Rush Medical College, Chicago, Illinos Department of Immunology/Microbiology, Rush Medical College, Chicago, Illinos
Alan A. Harris
Affiliation:
Department of Medicine, Rush Medical College, Chicago, Illinos
Mario Clerici
Affiliation:
Catteredra di Immunologia, Universita degli Studi di Milano, Milano, Italy
Jay A. Berzofsky
Affiliation:
National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Gene M. Shearer
Affiliation:
National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Harold A. Kessler*
Affiliation:
Department of Medicine, Rush Medical College, Chicago, Illinos Department of Immunology/Microbiology, Rush Medical College, Chicago, Illinos
*
Section of Infectious Diseases, Rush-Presbyterian-St Luke's Medical Center, 600 South Paulina, Ste 143 AAF, Chicago, IL 60612
Get access Rights & Permissions [Opens in a new window]

Abstract

We evaluated the effects of zidovudine postexposure prophylaxis (PEP) on the development of human immunodeficiency virus (HIV) envelope-specific cytotoxic T-lymphocyte responses in 20 healthcare workers with occupational exposures to HIV. Seven healthcare workers were treated with zidovudine PER Only 1 of 7 treated, versus 6 of 13 not treated, developed an HIV envelope-specific cytotoxic T-lymphocyte response. These data suggest that zidovudine abrogated HIV-specific cytotoxic T-lymphocyte responses. HIV-specific cytotoxic T-lymphocyte responses may be useful as a surrogate marker of HIV replication in the evaluation of new regimens for PEP of occupational HIV exposures.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 6 , June 1999 , pp. 428 - 430
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bureau of Labor Statistics. The Employment Situation. News Release. Washington, DC: Bureau of Labor Statistics; April 1997. Table 1.Google Scholar
2. Tokars, JI, Marcus, R, Culver, DH, Schable, CA, McKibben, PS, Bandea, CI, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913–919.CrossRefGoogle ScholarPubMed
3. Cardo, DM, Culver, DH, Ciesielski, CA, Srivastava, PU, Marcus, R, Abiteboul, D, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485–1490.CrossRefGoogle ScholarPubMed
4. Pinto, LA, Sullivan, J, Berzofsky, JA, Clerici, M, Kessler, HA, Landay, AL, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995;96:867–876.Google Scholar
5. Clerici, M, Lucey, DR, Zajac, RA, Boswell, RN, Gebel, HM, Takahashi, H, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of the gpl60 in HIV-seropositive individuals. J Immunol 1991;146:2214–2219.Google Scholar
6. Centers for Disease Control and Prevention. Update: Provisional Public Health Service recommendation for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468–472.Google Scholar
7. Royce, RA, Sena, A, Cates, W, Cohen, MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072–1078.Google Scholar
8. Henderson, DK, Fahey, BJ, Willy, M, Schmitt, JM, Carey, K, Kosiol, DE, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990;113:740–746.Google Scholar
9. Clerici, M, Giorgi, JV, Chou, CC, Gudeman, VK, Zack, JA, Gupta, P, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012–1019.Google Scholar
10. Rowland-Jones, S, Sutton, J, Ariyoshi, K, Dong, T, Gotch, F, McAdam, S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59–64.CrossRefGoogle ScholarPubMed